In short
Clinical trials are investigating VX-407 in people with autosomal dominant polycystic kidney disease (ADPKD) who have a subset of PKD1 gene variants. The study is looking at whether VX-407 can help in this group and is measuring outcomes such as kidney size changes over time.
Key points
- VX-407 is being studied in a Phase 2 clinical trial for people with autosomal dominant polycystic kidney disease (ADPKD) who have a subset of PKD1 gene variants. The trial is interventional, meaning participants receive the study treatment and are followed for results. The main outcome is based on changes in height-adjusted total kidney volume, measured by MRI over time. The study is authorised and plans to enroll 24 subjects. This trial is focused on a specific genetic group within ADPKD, not the broader ADPKD population.
Trial overview
The available trial data describe one interventional study of VX-407 in ADPKD. The study title says it is a Phase 2a study in subjects with ADPKD who have a subset of PKD1 gene variants.
The brief summary states that the study is for treatment of ADPKD with VX-407. The trial is listed as authorised and plans to enroll 24 people.
Who the study is for
This trial is focused on people with autosomal dominant polycystic kidney disease (ADPKD) who have a subset of PKD1 gene variants. In simple terms, the study is not for all people with ADPKD, but for a specific genetic group within that disease.
The trial record does not provide more detailed eligibility rules, such as age limits, kidney function limits, or other health requirements.
What the trial is testing
The study is testing VX-407 as a treatment for ADPKD. Because this is an interventional trial, participants receive the study treatment and researchers measure what happens over time.
The trial data do not describe the treatment plan in detail, so the main focus here is the study goal and the outcome being measured rather than how the product is given.
Study phase and status
The study is in Phase 2. Phase 2 studies usually look more closely at whether a treatment may help the target group and continue to gather safety information, although the trial record here only states the phase and does not give extra phase details.
The status is Authorised, which means the study has been approved to begin according to the trial record.
Main outcome measure
The primary outcome is the proportion of subjects with percent change from baseline in htTKV ≤0 on MRI over time. This means the study is looking at how kidney volume changes from the starting point, using MRI scans.
htTKV stands for height-adjusted total kidney volume, which is a way to measure kidney size while taking a person's height into account. In patient language, the trial is checking whether kidney size stays the same or becomes smaller over time in the study group.
Key patient points
- The study is for people with ADPKD who have a specific subset of PKD1 gene variants.
- It is a Phase 2 interventional trial, so the study treatment is given and then measured over time.
- The main measurement is kidney size on MRI, using htTKV as the key number.
- The trial is authorised and plans to enroll 24 subjects.